The document describes the UNC Eshelman School of Pharmacy as a recognized leader in pharmacy education, practice, and research. It provides details on its academic programs, research centers focused on drug discovery and development, and partnerships within UNC and with outside organizations. The School has over 100 faculty conducting research across therapeutic areas from discovery through clinical practice, and seeks to enhance its research enterprise through partnerships with industry.

1. side in Highlighting the research enterprise, educational outreach, and health care impact of our institution.

2. troduction in Our School A recognized leader in progressive pharmacy practice, education, and research

3. in troduction Our School in Numbers Ranked 2nd among professional pharmacy programs (PharmD) and 2nd in NIH funding (>$24M) in 2010 Over 100 faculty members, 600PharmD students, and 110 graduate students Over 200,000 sq ft of research and teaching space (3 buildings; 4th to be completed in 2013) with state-of-the-art video teleconference and distance education technology

4. in troduction Our Academic Programs PharmD PhD MS The professional degree program in pharmacy, leading to diverse careers across practice settings Graduate degree in pharmaceutical sciences with concentrations in: Medicinal Chemistry &Natural Products Molecular Pharmaceutics Pharmacotherapy & Experimental Therapeutics Pharmaceutical Outcomes & Policy Preparing pharmacists with the knowledge and skills necessary for assuming leadership positions in health care

5. tegrated in Our Structure Charting a course for drug discovery and development through education, innovation, and collaboration

7. Development

8. Education

9. Disease Targets

10. Leads

11. Formulation

12. Drug delivery

13. Disposition

14. Clinical Safety & Efficacy

15. Effectiveness of Delivery

17. novative in Our Research Centers Finding cutting-edge solutions to complex health challenges

19. Drug Leads

20. Target ValidationCICBDD Staff & Joint Faculty Center-Initiated Projects in Chemical Biology “Prospective Science”

21. in novative Our Research Centers Center for Integrative Chemical Biology & Drug Discovery (CICBDD) Center Capabilities Assay Development Protein expression and purification, multiple platforms and readouts Compound Screening Up to 100,000 compounds Medicinal Chemistry SAR projects, compound synthesis, internal chemists and access to more as-needed Computational Chemistry Screening set design, virtual screening, and structure-based design Features of the Center Access to biological targets across therapeutic areas Research focus on innovative targets in chromatin biology and epigentics Comprehensive Chemical Biology Center designated by the National Cancer Center (NCI) Leadership with industrial track record of FDA-approved drugs

22. in novative Our Research Centers Center for Nanotechnology in Drug Delivery (CNDD) Director Russ Mumper Safely and effectively translating new drug and imaging discoveries into clinical trials using nanotechnology with the goal of improving public health Five Critical Areas / Disciplines Chemistry & Biomaterials Institute for Advanced Materials Formulation & Drug Delivery UNC Eshelman School of Pharmacy Therapeutic & Diagnostic Targets Carolina Center of Cancer Nano-biotechnology Excellence Nano-toxicology RTP EPA NIEHS Phase I/II Clinical Trials UNC Clinical & Translational Science Awards 1 2 4 3 5

24. Stabilize NMEs

25. Increase cell accumulation

26. Varied dosage forms and routes of administration in pre-clinical models

27. Improved pharmacokinetics

28. Minimize toxicity

29. Cost-effectiveness

30. Scalable under GMP

31. CMC sections of INDIncreased Probability of Clinical Success

32. in novative Our Research Centers The Hamner-UNC Institute for Drug Safety Sciences (IDSS) Director Paul Watkins Integrating clinical medicine with cutting-edge systems biology and in silicomodeling platforms to make drugs safer and advance drug development A Platform for Integrated Drug Safety Research Predictive Safety Assessment In vitro In vivo Clinical Post-marketing Surveillance Computational Systems Modeling

34. UNC School of Nursing

35. UNC Gillings School of Global Public Health

36. Carolina Center for Genome Sciences

38. Clinical Pharmacogenomics

39. Evidence-based medicine

40. Medical Decision-making & Outcomes

41. Pre-clinical Pharmacogenomics

42. Pharmacoeconomics

43. Phenotype-driven Therapy

45. in terconnected Research Enterprise & Partnerships CICBDD Chemistry & Biology UNC Departments of Chemistry, Physics, Mathematics, and Computer Science Biomanufacturing Research Institute & Technology Enterprise UNC School of Medicine Lineberger Comprehensive Cancer Center UNC Neuroscience Center Carolina Cardiovascular Biology Center North Carolina Center for Nanoscale Materials Institute for Advanced Materials, Nanoscience & Technology UNC Institute for Nanomedicine Carolina Center of Cancer Nanotechnology Excellence Biomedical Research Imaging Center Bryson Center for Human Genetics North Carolina Translational and Clinical Sciences Institute Research Triangle Park Validate targets, confirm leads CNDD GLP Facility Nanotechnology & Engineering Create stable, lead formulations In Vivo Screening Develop efficacious pre-clinical lead formulations IPIT Genomics & Biology Link molecular genetics to efficacy

46. in terconnected Our Relationships At UNC Research Triangle Park HamnerInstitutes for Health Sciences US Environmental Protection Agency National Institute of Environmental Health Sciences (NIEHS) RTI International Pharmaceutical/Biotechnology Companies Carolina Center for Genome Sciences Gillings School of Global Public Health Institute for Advanced Materials, Nanoscience & Technology Lineberger Comprehensive Cancer Center School of Medicine Area Universities Pharmacy Spin-offs Cirrus NeuroGate Oriel Therapeutics Qualiber Qualyst Synereca Pharmaceuticals Capture Pharmaceuticals Duke University North Carolina Central University North Carolina State University Wake Forest University

47. spiring in Our People Driving discoveries and mentoring future clinicians and scientists

48. in spiring Our People · Discovery Functional Proteomics Chemical Biology & Medicinal Chemistry Glycobiology Qisheng Zhang, PhD Stephen Frye, PhD Harold Kohn, PhD Jian Liu, PhD Michael Jarstfer, PhD David Lawrence, PhD Rihe Liu, PhD NIMH-Psychoactive Drug Screening Program Chemoinformatics, Bioinformatics & Computation Structural Biology Protein Dynamics – NMR Natural Products Andrew Lee, PhD Alexander Tropsha, PhD Bryan Roth, MD, PhD KH Lee, PhD

49. in spiring Our People · Delivery Formulation & Drug Delivery Sam Lai, PhD Michael Jay, PhD Moo Cho, PhD Rudy Juliano, PhD Leaf Huang, PhD Russ Mumper, PhD Radiopharmaceutics & Imaging Michael Jay, PhD Richard Kowalski, PhD

50. in spiring Our People · Translation Transplant Pharmacotherapy Metabolism/Transport/PK/PD/Pharmacometrics Kim BrouwerPharmD, PhD Mary Paine PhD Dhiren Thakker, PhD Robert Dupuis, PharmD Philip Smith, PhD Julie Dumond, PharmD Adam Persky, PhD Cardiovascular Pharmacology Mechanisms of Hepatotoxicity Craig Lee, PharmD, PhD Kim BrouwerPharmD, PhD Roy Hawke PharmD, PhD Paul Watkins, MD Herbert Patterson, PharmD Jo Ellen Rodgers, PharmD

51. in spiring Our People · Translation Pharmacogenomics & Cancer Pharmacotherapy Infectious Diseases Pediatric Pharmacotherapy Angela Kashuba, PharmD Julie Dumond, PharmD Howard McLeod, PharmD Tim Wiltshire, PhD Angela Kashuba, PharmD Dhiren Thakker, PhD Christine Walko, PharmD Amanda Corbett, PharmD William Zamboni, PhD, PharmD Russ Mumper, PhD Michael Cohen-Wolkoweitz Lynn Dressler, DrPH Sam Lai, PhD William Zamboni, PhD, PharmD Federico Innocenti, MD, PhD

52. in spiring Our People · Outcomes Outcomes Research Betsy Sleath, PhD Susan Blalock, MPH, PhD Joel Farley, PhD Lynn Dressler, DrPH Jaya Rao, MD Mary Roth McClurg, PhD

55. Partnering with the School to support start-up companies or with start-ups

57. Faculty available for consulting

58. Seeking involvement of industry scientists to participate in teaching/training